RAS mutations drive ∼20% of human cancers. This review summarizes clinical outcomes and resistance mechanisms of KRASG12C inhibitors and highlights emerging classes of next-generation (K)RAS inhibitors, focusing on their mechanisms of action, selectivity, early efficacy, and potential to overcome resistance in RAS-driven tumors.
Cancer Cell published a clinical update in Oncology on 29 Jan 2026.
The item focuses on Emerging landscape of KRAS inhibitors in cancer treatment.
Review the original article for the full source wording and details.